Results from this subgroup analysis of the MONALEESA-2 trial demonstrate that ribociclib plus letrozole provides a valuable first-line therapy option for women who present with de novo HR+, HER2− advanced breast cancer at diagnosis. This evidence concerns the gene ERBB2 and breast carcinoma.